Celldex Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Celldex Therapeutics, Inc. - overview
Location
Needham, MA-Massachusetts, US
Primary Industry
Pharmaceuticals
About
AVANT Immunotherapeutics, Inc. is a biopharmaceutical company engages in the development and commercialization of vaccines and drugs.
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Verticals
HealthTech
Company Stage
PIPE
Total Amount Raised
Subscriber access only
Celldex Therapeutics, Inc. - timeline of key events
Celldex Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 9,265,000 | 11,202,000 | 4,111,000 | 3,586,000 | 5,480,000 | 6,786,000 | 12,743,000 | 9,538,000 | 3,573,000 | 7,418,000 | 4,651,000 | 2,357,000 | - | - | - |
| % Revenue Growth (YoY) | - | 20.9% | (63.3%) | (12.8%) | 52.8% | 23.8% | 87.8% | (25.2%) | (62.5%) | 107.6% | (37.3%) | (49.3%) | - | - | - |
| EBITDA (USD) | (39,221,000) | (55,600,000) | (79,863,000) | (118,934,000) | (125,180,000) | (127,898,000) | (116,507,000) | (153,683,000) | (51,313,000) | (60,154,000) | (64,966,000) | (111,494,000) | - | - | - |
| Operating Income (USD) | (43,399,000) | (58,077,000) | (81,442,000) | (122,430,000) | (129,541,000) | (132,916,000) | (121,527,000) | (156,436,000) | (55,031,000) | (63,354,000) | (71,243,000) | (115,234,000) | - | - | - |
| Operating Margin | (468.4%) | (518.5%) | (1981.1%) | (3414.1%) | (2363.9%) | (1958.7%) | (953.7%) | (1640.1%) | (1540.2%) | (854.1%) | (1531.8%) | (4889.0%) | - | - | - |
| % EBITDA Margin | (423.3%) | (496.3%) | (1942.7%) | (3316.6%) | (2284.3%) | (1884.7%) | (914.3%) | (1611.3%) | (1436.1%) | (810.9%) | (1396.8%) | (4730.3%) | - | - | - |
| NET Income (USD) | (44,799,000) | (59,123,000) | (81,550,000) | (118,080,000) | (127,197,000) | (128,530,000) | (93,031,000) | (151,184,000) | (50,878,000) | (59,780,000) | (70,511,000) | (112,325,000) | - | - | - |
| % Net Margin | (483.5%) | (527.8%) | (1983.7%) | (3292.8%) | (2321.1%) | (1894.0%) | (730.1%) | (1585.1%) | (1424.0%) | (805.9%) | (1516.0%) | (4765.6%) | - | - | - |
Celldex Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Celldex Therapeutics, Inc. | - | ||||||||
| Unspecified Round | Completed | Celldex Therapeutics, Inc. | - |
Displaying 1 - 2 of 2
Celldex Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.